

**Table S2. Proportion of participants who received 2012-13 TIV<sup>a</sup> by age and influenza type, subtype and lineage**

Age (years)	Negative	Influenza	Influenza A	A/H3N2	A(H1N1)pdm09	Influenza B	B/Yamagata (vaccine)	B/Victoria (non-vaccine)
	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)	n/N (%)
<b>1-8</b>	18/96 (19)	5/104 (5)	4/73 (5)	3/66 (5)	0/4 (0)	1/31 (3)	1/25 (4)	0/5 (0)
<b>9-19</b>	10/86 (12)	0/98 (0)	0/60 (0)	0/52 (0)	0/6 (0)	0/38 (0)	0/21 (0)	0/16 (0)
<b>20-49</b>	73/401 (18)	36/279 (13)	29/221 (13)	24/166 (14)	5/50 (10)	7/58 (12)	4/28 (14)	2/23 (9)
<b>50-64</b>	57/177 (32)	26/118 (22)	23/91 (25)	19/74 (26)	3/15 (20)	3/27 (11)	1/20 (5)	1/3 (33)
<b>65+</b>	66/89 (74)	28/53 (53)	22/40 (55)	20/36 (56)	2/4 (50)	6/13 (46)	3/4 (75)	2/7 (29)
<b>Total</b>	224/849 (26)	95/652 (15)	78/485 (16)	66/394 (17)	10/79 (13)	17/167 (10)	9/98 (9)	5/54 (9)

TIV=trivalent influenza vaccine. Note that where influenza A/subtype or B/lineage tallies do not sum to total influenza A or B detections, it is owing to missing subtype- or lineage-level information.

- a. TIV receipt two weeks or more before onset of influenza-like symptoms per vaccine effectiveness analysis